Hyperion DeFi, Inc (HYPD) Fair Value & Analysis
Healthcare · US · Market cap $52.3M
Hyperion DeFi, Inc
HYPD · US
Fair value as of: Jul 16, 2026
From 1 valuation models · updated today
Share price +3.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.52 – $15.97 · fair‑value band $1.15 – $2.30 · the $3.02 price screens above the $1.54 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hyperion DeFi, Inc (HYPD) currently trades at $3.02, while our model-based Fair Value estimate is $1.54 — implying the stock looks roughly 49.1% overvalued today. We read business quality at 18/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $1.0M. Net debt stands at $2.1M. Fundamentals as of Jul 16, 2026
Our scenario range runs from $1.15 (bear case) to $2.30 (bull case); at $3.02, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -17% fair-value upside — at -49%, HYPD screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem. It is also developing the Optejet User Filled Device to work with various topical ophthalmic liquids, including artificial tears and lens rewetting products. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in Dallas, Texas.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hyperion DeFi, Inc reported revenue of $813K in FY2025 versus $14.0M in FY2021, a compound −50.9%/yr. Reported net income was −$45.3M in FY2025.
Is HYPD fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $618.03 | $594.40 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hyperion DeFi, Inc (HYPD) undervalued?
What is the fair value of HYPD?
What is the quality score of HYPD?
What is the revenue of Hyperion DeFi, Inc (HYPD)?
What is the net profit margin of HYPD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Tell me when Hyperion DeFi, Inc reaches its Fair Value
Just your email — and we'll notify you when the price and Fair Value of Hyperion DeFi, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.